530 results about "Auto immune" patented technology

The invention relates to the technical field of microorganisms, in particular to a bifidobacterium animalis subsp. Lactis and application thereof, and particularly provides a bifidobacterium animalis subsp. Lactis BX-BC08 which is beneficial for restoring the microecological balance of the intestinal tract and enhancing the immune barrier function of the intestinal tract. Experiments prove that the bifidobacterium animalis subsp. Lactis BX-BC08 disclosed by the invention can regulate an immune system and relieve excessive immune response, can reduce generation of inflammatory factors and relieve skin inflammation symptoms for autoimmune related diseases such as atopic dermatitis, is relatively good in tolerance to a human body, and greatly reduces adverse reaction of the human body.

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides methods of treating aging, senescence, fibrosis, autoimmunity, cancer, infection, and / or immune disease using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein, as well as methods of identifying the agents.

The invention discloses an OTX-015 (Ox-015) loaded cascaded responsive nano particle and a preparation method thereof. The nanoparticle has a three-layer core-shell structure, wherein the innermost layer is a cross-linked nanoparticle of chitosan and paclitaxel; the middle layer is a polydopamine layer loaded with a bromodomain inhibitor OTX-015; the outermost layer is a gelatin layer grafted with babali; wherein the cross-linked substance of the chitosan and the paclitaxel is a cross-linked substance containing a disulfide bond. The invention also provides a preparation method of the cascade responsive nano-particle and application of the cascade responsive nano-particle in preparation of an antitumor drug targeted delivery system. The nanoparticle provided by the invention improves the tumor microenvironment while activating in-vivo autoimmunity, and kills tumor cells by using photothermal therapy assisted chemotherapy drugs, so that the synergistic effect of chemotherapy / photothermal therapy / immunotherapy is realized, and a new idea is provided for clinical tumor treatment.

The present invention relates to autoantibodies against NaV1.5 channel, their use as biomarker for the diagnosis of Brugada syndrome in human beings and relative methods of detection and therapeutic approach to target this new discovered form of autoimmunity.

The invention discloses a method for screening by combining a space transcriptome and CRISPR (clustered regularly interspaced short palindromic repeats) in a same unbiased mode and application of the method in gene function verification, and belongs to the technical field of biology. The method comprises the following steps: infecting target cells with CRISPR screening library viruses; sorting out positively infected target cells, and culturing for a period of time after knockout; injecting the target cells obtained in the previous step into an experimental animal body, wherein the experimental animal is an animal with autoimmunity deficiency; taking out tissues infiltrated by the target cells, and preparing frozen sections; transferring the frozen section to a spatial transcriptome slide, and loading on a machine to prepare a spatial transcriptome cDNA library; constructing a common transcriptome library and a CRISPR sgRNA library by using the space transcriptome cDNA library; and respectively carrying out sequencing and gene sequence comparison on the common transcriptome library and the CRISPR sgRNA library to obtain common transcriptome sequencing data carrying space coordinates and CRISPR sgRNA library sequencing data carrying space coordinates.

The invention provides a complementary determining region 3 and immune epitope binding prediction method, and belongs to the field of bioinformatics. According to the method, multi-modal heterogeneous graph modeling, a graph attention network (GAT) and multi-objective loss function collaborative optimization are fused, and the method aims at breaking through the limitation of the prior art in the aspects of heterogeneous data modeling, class imbalance, prediction precision and the like. A heterogeneous graph of 3 nodes of a complementary determining region and immune epitope nodes is constructed, GAT is introduced to realize cross-modal feature interaction, and a dynamic weight optimization strategy of a focus loss function and an AUC loss function is combined, so that the recognition capability and the overall sorting performance of the model on difficult samples are improved. And meanwhile, interpretable analysis combined with the hotspot residues is realized through the attention weight. According to the method, the prediction accuracy of the binding specificity of the complementarity determining region 3 and the immune epitope is remarkably improved, and the method can be widely applied to cancer vaccine design, individualized immunotherapy and autoimmune disease research and has important theoretical significance and practical application value.

The invention relates to a pyrimidopyrrole derivative and application thereof in medicine, in particular to a compound shown in a general formula (I) or a stereoisomer, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal of the compound, an intermediate and a preparation method of the compound, and application of the compound in BTK related diseases such as tumors or autoimmune system diseases. # imgabs0 #

The invention discloses an arabidopsis thaliana RK3 gene and application of S structural domain receptor kinase RK3 coded by the arabidopsis thaliana RK3 gene in improvement of plant disease resistance, and belongs to the technical field of plant genetic engineering. According to the application of the arabidopsis thaliana RK3 gene to improvement of plant disease resistance, the nucleotide sequence of the arabidopsis thaliana RK3 gene is shown as SEQ ID NO.1, the amino acid sequence of S structural domain receptor kinase RK3 coded by the arabidopsis thaliana RK3 gene is shown as SEQ ID NO.2, and further plants are selected from arabidopsis thaliana, oilseed rape, rice, tomatoes, potatoes, peanuts, soybeans, cotton, tobacco, cucumbers, watermelons and the like. The expression of the plant disease resistance comprises infection resistance to wild-type pseudomonas syringae, effector engineering strains thereof and botrytis cinerea. It is clear that the arabidopsis thaliana RK3 gene and the encoded protein thereof can remarkably enhance the infection resistance of plants to various pathogenic bacteria for the first time, disease prevention and control are achieved by activating the autoimmune system of the plants, and an effective path is provided for reducing chemical pesticide application and promoting agricultural green development.

The invention discloses a chimera for degrading a CARD structural domain protein aggregate and application of the chimera. The chimera is prepared from light-operated targeting protein and light-operated degradation protein, the light-operated targeting protein is sequentially connected by an MAVS CARD structural domain, a flexible connecting peptide and a photosensitive protein pMag; the light-controlled degradation protein is sequentially connected by a photosensitive protein nMag, a flexible connecting peptide and an RING structural domain of TRIM21. According to the application, a light-operated activated CARD-RING chimera is constructed, and when the CARTAC generates toxic and side effects or in cells with RIG-I / MDA5 signal channels abnormally activated, the activity of the CARTAC can be effectively controlled or autoimmune diseases caused by RIG-I / MDA5 abnormity can be inhibited.

The present invention provides EGFR and c-MET bispecific antibodies, antigen binding portions thereof, other binding agents and EGFR and c-MET bispecific conjugates thereof, as well as methods and uses of such antibodies and conjugates for the treatment of cancer and autoimmune disease.

The invention belongs to the field of new application of medicines, and particularly relates to application of SIRT4-IN-1 in preparation of medicines for treating autoimmune diseases. It is found for the first time that SIRT4-IN-1 reduces the activation degree of immune response induced by HSV-1 virus infection by up-regulating acetylation modification of cGAS, inhibits abnormal activation of immune response in Trex1 deficient mouse cells and peripheral blood mononuclear cells of systemic lupus erythematosus patients, and improves abnormal activation of autoimmune response. The invention provides a new candidate drug for clinical treatment of systemic lupus erythematosus.

Methods and systems for detecting one or more autoantibodies and / or analytes associated with one or more clinical feature or outcome, such as an autoimmune and related disease or other disease through binding events on a biomolecule array. Kinetic parameters of the binding events can be determined. The kinetic parameters may be used to identify one or more clinical feature or outcome, such as diagnose one or more disease, such as an autoimmune and related disease, and / or to provide a prognosis of one or more disease. The kinetic parameters may be used as inputs in one or more machine learning algorithms to identify associations and / or correlations between one or more kinetic parameter and / or other additional information and one or more clinical feature or outcome.

The invention discloses a preparation method of a stem cell exosome chitosan compound covered stent. The stem cell exosome chitosan compound comprises a stem cell exosome and a chitosan compound. In the stem cell exosome and chitosan compound, the mass percent of chitosan is 3%-10%, and the number of the stem cell exosomes is 109-1011. Compared with a traditional covered stent, the covered material provided by the invention can resist inflammation, inhibit bacteria, protect vascular endothelial cells covered by the stent, promote tissue repair, prevent tissue adhesion, prevent fibrosis and inhibit exclusion reaction and autoimmunity.

Provided here are methods to prevent, inhibit or treat an autoimmune disease or a vascular or cardiovascular disorder in a mammal, comprising administering to the mammal a composition comprising an effective amount of isolated nucleic acid comprising a nucleotide sequence encoding WDFY3 / Alfy or a portion thereof, a nucleotide sequence comprising a WDFY3 / Alfy-specific long non-coding RNA (lncRNA) or a corresponding DNA sequence, a nucleotide sequence comprising a portion of a lncRNA WDFY3-AS2 or a corresponding DNA sequence, or isolated WDFY3 / Alfy or a portion thereof.

Methods of preventing or treating autoimmune disease are disclosed. In some cases, subjects with having or at risk of developing autoimmune disease are identified as possessing one or more autoimmunity-susceptibility HLA alleles at one or more HLA loci. In many cases, the HLA loci are selected from Class I and Class II loci, for example Class I A, B, and C, and Class II DQ, DR, and DP. In many cases, subjects suffering from or at risk of developing an autoimmune disease may be administered a plurality engineered autologous HSCs modified to carry and express a variant susceptibility allele having at least one mutation in the antigen binding cleft that alters antigen binding and / or specificity of that variant HLA molecule. In many embodiments, the engineered HSCs are CD34+ immune cells that express one or more modified HLA proteins.

Provided herein are antibodies and antibody fragments that bind to human TNFRSF25. The antibodies may be monoclonal and / or biparatopic antibodies and / or single- chain fragment variable (scFv) antibodies. Methods of treating or preventing diseases or disorders associated with inflammation and / or autoimmunity are provided, comprising administering to a patient in need thereof an effective amount of a human TNFRSF25- binding antibody.

Provided herein are systems and methods for identifying a disease or disorder of a patient, identifying if a patient is likely to respond to a treatment for the disease or disorder, and / or predicting the clinical outcome of the disease or disorder of a patient. Systems and methods described herein may be directed to patients with different chronic conditions, inflammatory conditions, and / or autoimmune conditions. Systems and methods described herein may be directed to patients with a dermatological condition.

Provided herein are compositions and methods for the treatment of an autoimmune or inflammatory disease, such as rheumatoid arthritis. Said compositions comprise a TNFR1 inhibitor. Some embodiments comprise combination therapy featuring the TNFR1 inhibitor with at least one additional anti-inflammatory therapeutic agent.

The invention provides a semi-supervised learning method, system and device for predicting functional regulation variation and a storage medium. Comprising the following steps: mutating an intersection in a processed GWAS data set and an InuNexUT data set, and dividing mutated data into a training set, a verification set and a test set; a test set for experimental verification is constructed on the basis of HGMD and ClinVar data sets, a training set is used for pre-training a convolutional neural network model, and then a semi-supervised convolutional neural network model is constructed on the basis of variation which does not intersect with GWAS and InuNexUT. Finally, the processed data set is applied to the sscNOVA model, the availability of the sscNOVA model is proved, the method is the first prediction method capable of recognizing the functional regulation and control variation related to the autoimmune disease based on the sequence, and the ideal prediction effect is achieved.

The present invention provides prodrugs, methods of preparation thereof, and uses thereof in stimulating the immune system, treating cancer, autoimmune diseases, or infectious diseases.

The invention belongs to the field of biological medicine, and particularly relates to a varicella-zoster virus gB protein mutant and application thereof. According to the gB protein mutant of the varicella-zoster virus, provided by the invention, proline mutation, shearing of N-terminal and C-terminal structural domains, release of electrostatic repulsive force in the protein, mutation of a Frelin enzyme cutting site and the like are carried out in a process of converting a gB protein fusion precursor into a fusion afterbody conformation, so that the gB protein mutant of the varicella-zoster virus is obtained. The conformation before fusion can be stabilized, and the expression quantity and the stability of the antigen protein are improved. As a vaccine component, the mutant has good immunogenicity, activates autoimmunity of animals and plays a role in prevention or treatment of vaccines.

The invention belongs to the technical field of immunology, and particularly discloses an in-vitro preparation method and application of an induced follicular regulatory T cell iTfr.The in-vitro preparation method comprises the steps that mouse spleen single-cell suspension or healthy human peripheral blood is obtained, peripheral blood mononuclear cells are obtained, then initial CD4 + T cells are obtained through immunomagnetic bead sorting, and iTfr cells are obtained; then carrying out induced differentiation by using an antibody and a specific cytokine, and carrying out continuous stimulation and culture by adopting two different cytokine polarization conditions, so as to obtain the iTfr cell. The invention provides a method for preparing the iTfr cells in vitro, which is expected to obtain an enough number of induced follicular regulatory T cells, and provides an important tool and a treatment means for in vitro research of immune tolerance related diseases such as autoimmune diseases and organ transplantation.

The present disclosure is directed toward drugs or toxins; drug conjugates comprising said drugs or toxins and a cleavable linker; and conjugates comprising said drugs or toxins, cleavable linkers, and cell-binding groups. The present disclosure also relates to methods of treating cancers, autoimmune diseases, and inflammatory diseases using the compounds and conjugates of the disclosure.

The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial ensembles, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial compositions, and compositions comprising the same, in methods for treating or preventing gastrointestinal enteropathy or dysbiosis in canines. In particular aspects, the disclosure provides methods of treating or preventing morbidity and mortality caused by GI pathogenesis or autoimmunity.

An antibody that specifically binds to IL-1R3, comprising an antibody heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2. A pharmaceutical composition is provided comprising the said antibody and a pharmaceutically acceptable diluent, carrier or excipient. Also said antibody for use in treating a disease or disorder in a subject in need thereof. The disease or disorder may be an autoimmune or autoinflammatory disease or disorder.

Provided herein is a method of preventing or treating an immune disorder, autoimmune disorder or an inflammatory condition in a person in need thereof, comprising administering to the person a therapeutically effective amount of an LDH inhibitor. Specifically, provided herein are substituted pyrazolyl compounds as Lactate dehydrogenase A (LDHA) inhibitors, methods and uses of the LDHA inhibitors and / or a pharmaceutically acceptable salt thereof in preventing or treating an immune disorder, an inflammatory condition, or a fibrosis disease.

A multi-dimensional body positioning apparatus that can be used in the practice of pilates, yoga, tai chi, and other intelligent movement disciplines, including exercise, rehabilitation, training, physical and mental conditioning, habituation, injury prevention and recovery; in medical protocols for minimizing cascade of disabilities and maximizing muscular and neurological recovery from paralysis, congenital disorders, and auto immune illnesses; and overall healing. The body positioning apparatus includes raised portions that are plateaus that relate to the topology of the human body, which provide visual and tactile references, so the user can properly align the body during exercise or use of the apparatus. By providing these plateaus, the exercise routine can be optimized. For instance, a user can us the apparatus supervised while monitoring proper technique.

The invention discloses a dental ulcer image recognition autoimmune disease blood index correlation analysis system, and relates to the technical field of medical informatics. Comprising a time sequence data acquisition module, a steady state baseline construction module, a cross-modal synchronous analysis module, a deviation degree calculation module, a disease risk judgment module and a risk early warning output module. The system constructs an individualized immune steady-state baseline by acquiring a dental ulcer image of a user and time sequence data of blood indexes related to autoimmunity; the image lesion dynamic evolution rate is used as a guide factor, time extrapolation is carried out on the blood indexes collected asynchronously, and synchronous predictive immune data are generated; by calculating the deviation degree of the prediction data and the steady state baseline, accurate and real-time judgment and early warning of the autoimmune disease risk are realized. According to the invention, the problem of evaluation delay caused by desynchrony of dental ulcer image and blood index acquisition time is effectively solved, and the timeliness and accuracy of health risk monitoring are improved.

A polycyclic fused-ring BTK degradation agent and a use thereof in medicine. Specifically, the present invention relates to a compound of general formula (I) or a stereoisomer, tautomer, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or cocrystal thereof, an intermediate thereof and a preparation method therefor, and a use in BTK-related diseases, such as tumors or autoimmune system diseases, preferably relapsed / refractory B-cell malignancies.

Methods of preventing or treating autoimmune disease are disclosed. In some cases, subjects with having or at risk of developing autoimmune disease are identified as possessing one or more autoimmunity-susceptibility HLA alleles at one or more HLA loci. In many cases, the HLA loci are selected from Class I and Class II loci, for example Class I A, B, and C, and Class II DQ, DR, and DP. In many cases, subjects suffering from or at risk of developing an autoimmune disease may be administered a plurality engineered autologous HSCs modified to carry and express a variant susceptibility allele having at least one mutation in the antigen binding cleft that alters antigen binding and / or specificity of that variant HLA molecule. In many embodiments, the engineered HSCs are CD34+ immune cells that express one or more modified HLA proteins.